SBIR Phase I: Gene signature screening for Pancreatic Cancer Therapeutics from Sonoran Desert extracts

SBIR 第一阶段：从索诺兰沙漠提取物中筛选胰腺癌治疗药物的基因特征

• 批准号: 1014372
• 负责人: Richard Kris
• 金额: --
• 依托单位: Nuvogen Research
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1014372&HistoricalAwards=false
• 关键词: SBIR; Phase; Gene; signature; screening

This Small Business Innovation Research (SBIR) Phase I project is designed to discover compounds from a unique Natural Products Library that block the altered patterns of gene expression seen in pancreatic cancer. The extract and fraction library to be screened is from Dr. Gunatilaka at the University of Arizona and are derived from Sonoran desert plants and their associated microorganisms. These organisms have a high capacity to produce a variety of secondary metabolites, often in large quantities, which are essential for their survival as they are constantly exposed to a harsh, hot and dry environment. Thus, these extracts may contain a wealth of pharmacologically important small molecules. The first goal will be to identify extracts that block pancreatic-cancer-specific gene expression and then test whether they are also capable of inhibiting growth/proliferation of pancreatic cancer cells. The long term goal is to develop a targeted therapeutic for pancreatic cancer.The broader/commercial impacts of this research are novel non-toxic drugs that can treat pancreatic cancer for which no effective therapy exists. Pancreatic cancer ranks fourth among the leading causes of cancer deaths in the United States with an estimated death toll of 35,240 for 2009, roughly equal to the number of new patients for the same year. An effective therapeutic would reduce direct medical costs for treatment, estimated to be $881 million annually in the US, including hospitalization costs, outpatient costs, and home and long-term care. In addition it would hold the hope of returning patients to a productive life.

这个小企业创新研究（SBIR）第一阶段项目旨在从一个独特的天然产物库中发现化合物，这些化合物可以阻断胰腺癌中基因表达模式的改变。待筛选的提取物和级分文库来自亚利桑那大学的Gunatilaka博士，并且来自索诺兰沙漠植物及其相关微生物。这些生物体有很高的能力产生各种次级代谢物，往往是大量的，这是他们的生存所必需的，因为他们不断暴露在恶劣，炎热和干燥的环境。因此，这些提取物可能含有丰富的非生物重要的小分子。第一个目标将是鉴定阻断胰腺癌特异性基因表达的提取物，然后测试它们是否也能够抑制胰腺癌细胞的生长/增殖。长期目标是开发针对胰腺癌的靶向治疗药物。本研究的更广泛/商业影响是新型无毒药物，可以治疗目前尚无有效治疗方法的胰腺癌。胰腺癌在美国癌症死亡的主要原因中排名第四，2009年估计死亡人数为35，240人，大致等于同年的新患者数量。一种有效的治疗方法将减少治疗的直接医疗费用，估计在美国每年为8.81亿美元，包括住院费用，门诊费用以及家庭和长期护理。此外，它还有望使患者重新过上富有成效的生活。